The Influence of Metformin on the Indices of Thyroid Panel, Carbohydrate and Lipid Metabolism in Patients with Diffuse Toxic Goiter and Insulin Resistance
The goal of this investigation was to study the influence of metformin on the indices of thyroid hormones, carbohydrate and lipid metabolism in patients with diffuse toxic goiter and insulin resistance. The article presents the results of the study of 21 patients with diffuse toxic goiter. Treatment was conducted in two phases and each phase lasted for 3 months. During the first phase all patients received thyreostatic therapy with thyrozol, metformin was additionally prescribed in order to correct insulin resistance on the second phase. The obtained results are the evidence in favor of HOMA-IR index normalization by reducing glucose and fasting insulin, and slight increase in thyroid stimulating hormone and free thyroxine reduction within the referential standards against the background of combined treatment with thyrozol and metformin.
Borovikov V. Statistica: the art of analysis on PC. For professionals. S-Pb: Piter, 2001. – 656 p. Russian
Unified clinical protocol of primary and secondary (specialized) medical aid. Type 2 diabetes mellitus / International journal of endocrinology. 2013;1:116-169. Ukrainian
Garber A.J., Abrahamson M.J., Barzilay J.I. [et al.]. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm consensus statement. Endocr. Pract. 2013;19(2):536–557.
Beylot M. Laville М. Thyroid hormones and intermediary metabolism. The thyroid and tissues. Schattauer, Stuttgart and New York.1994;21(3):47–59.
Brenta G., Danzi S., Klein I. Potential therapeutic applications of thyroid hormone analogs. Nature Clinical Practice Endocrinology and Metabolism.2007;3:632–640.
Brenta G. Diabetes and thyroid disorders. British Journal of Diabetes & Vascular Disease. 2010;10(4):Р. 172–177.
Cappelli C., Rotondi M., Pirola I. et al. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care. 2009;32(9):1589–1590.
Coller F.A., Huggins C.B. Effect of hyperthyroidism upon diabetes mellitus: striking improvement in diabetes mellitus from thyroidectomy. Annals of Surgery. 1927;86:877–884.
Duntas L.H., Orgiazzi J., Brabant G. The Interface between thyroid and diabetes mellitus. Clin. Endocrinol. (Oxf.). 2011 Feb 24. – Doi 10.1111/j.1365–2265.2011.04029.
Kadiyala R., Peter R., Okosieme O. Thyroid dysfunctionin patients with diabetes: clinical implications and screening strategies. International Journal of Clinical Practice. 2010;64:P.1130–1139.
Kapadia K., Bhatt P., Shah J. Association between altered thyroid state and insulin resistance. Journal of Pharmacology and Pharmacotherapeutics. 2012;3:156-160.
Klieverik L.P., Janssen S.F., Riel A. et al. Thyroid hormone modulates glucose production via a sympathetic pathway from the hypothalamic paraventricular nucleus to the liver. Proc. Natl. Acad. Sci. U. S. A. 2009;106:5966–5971.
Pierre J., Tappy L., Scazziga B. еt аl. Insulin sensitivity and exogenous insulin clearance in Graves’ disease. Diabetes. 2014;35(2):178–181.
Sundaram V. Hanna A. Koneru N. Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation. Journal of Clinical Endocrinology and Metabolism. 1997;82(10):3421–3424.
Tene C., Zarete A., Basurto L. et al. Correction of insulin resistance in methimazole – treated patients with Graves’ disease. Rew Invest Clin. 2001;53(6):531–535.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2020